MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Moh'd Khushman, M.D.
Washington University School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Washington University School of Medicine
St Louis, Missouri, United States
Benjamin Tan, M.D.Chunjie Li, M.D., Ph.D.Esther Lu, Ph.D.Kian-Huat Lim, M.D., Ph.D.Mark O'Hara, M.D.Max Wattenberg, M.D.Moh'd Khushman, M.D.Nikolaos Andreatos, M.D.Nikolaos Trikalinos, M.D.Olivia Aranha, M.D., Ph.D.Patrick Grierson, M.D., Ph.D.Rama Suresh, M.D.Ramon Jin, M.D., Ph.D.Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Jun 2025
- Primary completion
- 30 Jun 2027
- Completion
- 31 May 2030
- Last update posted
- 30 Apr 2026
- Registered enrollment
- 51
- Registry id
- NCT06648434
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.